/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Cingulate Inc Share Price Today: Live Updates & Key Insights

Cingulate Inc share price today is $7.25, up -1.73%. The stock opened at $7.1 against the previous close of $7.51, with an intraday high of $7.91 and low of $6.6.

Cingulate Inc Share Price Chart

style
pb-0

Cingulate Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Cingulate Inc Share Price Performance

$7.25 -0.0173(-1.73%) CING at 23 Mar 2026 12:28 PM Biotechnology
Lowest Today 6.6
Highest Today 7.91
Today’s Open 7.1
Prev. Close 7.51
52 Week High 11.89
52 Week Low 3.20
Day’s Range: Low 6.6 High 7.91
52-Week Range: Low 3.20 High 11.89
1 day return -
1 Week return -31.41
1 month return +20.98
3 month return +76.97
6 month return +93.7
1 year return +88.26
3 year return -59.44
5 year return -91.67
10 year return -

Cingulate Inc Institutional Holdings

Vanguard Group Inc 1.38

Vanguard Total Stock Mkt Idx Inv 0.95

Kestra Advisory Services, LLC 0.86

Vanguard Institutional Extnd Mkt Idx Tr 0.59

Geode Capital Management, LLC 0.56

Fidelity Extended Market Index 0.34

Quadrature Capital Limited 0.14

Northern Trust Corp 0.12

Virtu Financial LLC 0.10

LPL Financial Corp 0.10

Quantum Private Wealth, LLC 0.09

Soltis Investment Advisors, LLC 0.09

Bank of America Corp 0.07

Fidelity Total Market Index 0.06

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

Spartan Extended Market Index Pool F 0.06

Fidelity Series Total Market Index 0.05

Spartan Total Market Index Pool G 0.05

NT Ext Equity Mkt Idx Fd - NL 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - L 0.03

HARBOUR INVESTMENTS, INC. 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

UBS Group AG 0.01

Tower Research Capital LLC 0.01

Advisor Group Holdings, Inc. 0.01

NT US Market Cap Idx Fd - L 0.00

Citigroup Inc 0.00

Commonwealth Equity Services Inc 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

SBI Securities Co Ltd 0.00

Susquehanna International Group, LLP 0.00

XTX Topco Ltd 0.00

Cingulate Inc Market Status

Strong Buy: 1

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Cingulate Inc Fundamentals

Market Cap 80.73 M

PB Ratio 23.2398

PE Ratio 0.0

Enterprise Value 79.19 M

Total Assets 15.07 M

Volume 1184015

Cingulate Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-21205277 -21.2M, FY22:-17850232 -17.9M, FY21:-20740493 -20.7M, FY20:-7283867 -7.3M, FY19:-11445336 -11.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-106782 -0.1M, Q2/2025:-146989 -0.1M, Q1/2025:-165291 -0.2M, Q3/2024:-3282087000 -3282.1M, Q2/2024:-3206180000 -3206.2M

Quarterly Net worth Q3/2025:-7341062 -7.3M, Q2/2025:-4788735 -4.8M, Q1/2025:-3802691 -3.8M, Q3/2024:-3231604000 -3231.6M, Q2/2024:-3209677 -3.2M

About Cingulate Inc & investment objective

Company Information Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Dr. Shane J. Schaffer Pharm.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Cingulate Inc FAQs

What is the share price of Cingulate Inc today?

The current share price of Cingulate Inc is $7.25.

Can I buy Cingulate Inc shares in India?

Yes, Indian investors can buy Cingulate Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Cingulate Inc shares in India?

You can easily invest in Cingulate Inc shares from India by:

Can I buy fractional shares of Cingulate Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Cingulate Inc?

Cingulate Inc has a market cap of $80.73 M.

In which sector does Cingulate Inc belong?

Cingulate Inc operates in the Biotechnology sector.

What documents are required to invest in Cingulate Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Cingulate Inc?

The PE ratio of Cingulate Inc is N/A and the PB ratio is 23.24.